Kantarjian HM - Search Results

1

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.

Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Verstovsek S, et al. Among authors: kantarjian hm. Blood. 2012 Aug 9;120(6):1202-9. doi: 10.1182/blood-2012-02-414631. Epub 2012 Jun 20. Blood. 2012. PMID: 22718840 Free PMC article.

2

Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis.

Robertson LE, Huh YO, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S, Kantarjian H, Keating MJ. Robertson LE, et al. Blood. 1992 Jul 1;80(1):29-36. Blood. 1992. PMID: 1377051 Free article.

3

Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.

Lee MS, Kantarjian H, Talpaz M, Freireich EJ, Deisseroth A, Trujillo JM, Stass SA. Lee MS, et al. Blood. 1992 Apr 15;79(8):1920-3. Blood. 1992. PMID: 1562719 Free article.

4

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.

Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Estey E, et al. Blood. 1992 May 1;79(9):2246-55. Blood. 1992. PMID: 1571541 Free article.

5

Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity.

Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M. Estrov Z, et al. Blood. 1991 Sep 15;78(6):1476-84. Blood. 1991. PMID: 1715791 Free article.

6

Therapy of chronic myelogenous leukemia with recombinant interferon-gamma.

Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU. Kurzrock R, et al. Blood. 1987 Oct;70(4):943-7. Blood. 1987. PMID: 3115339 Free article.

7

Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.

Drach D, Estrov Z, Zhao S, Drach J, Cork A, Collins D, Kantarjian H, Andreeff M. Drach D, et al. Leuk Lymphoma. 1994 Dec;16(1-2):79-88. doi: 10.3109/10428199409114143. Leuk Lymphoma. 1994. PMID: 7535143

8

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.

O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M. O'Brien S, et al. Blood. 1995 Nov 1;86(9):3322-6. Blood. 1995. PMID: 7579434 Free article.

9

Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.

Marlton P, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich EJ, Estey E. Marlton P, et al. Leukemia. 1995 Jun;9(6):965-71. Leukemia. 1995. PMID: 7596186

10

Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.

O'Brien S, Kantarjian H, Beran M, Robertson LE, Koller C, Lerner S, Keating MJ. O'Brien S, et al. Blood. 1995 Aug 15;86(4):1298-300. Blood. 1995. PMID: 7632936 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,089 results

Search Page

Filters